Sustained Negativity for HCV-RNA over 24 or More Months by Long-Term Interferon Therapy Correlates with Eradication of HCV in Patients with Hepatitis C Virus Genotype 1b and High Viral Load
- 1 February 2004
- journal article
- research article
- Published by S. Karger AG in Intervirology
- Vol. 47 (1), 19-25
- https://doi.org/10.1159/000076638
Abstract
Objective: We assessed whether sustained negativity for HCV-RNA over 24 or more months by long-term interferon (IFN) therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load or not. Methods: The number of patients with HCV-genotype 1b and high viral load exceeding 1 Meq/ml who received 6 MU of natural IFN-α daily for 2–8 weeks, followed by three times/week for 16–22 weeks and negativity for HCV-RNA during IFN administration was 403. Forty-one of 403 patients received 6 MU of natural IFN-α three times/week for more than 18 months after the initial IFN therapy (long-term-IFN-group). Three hundred and two patients did not receive any IFN treatment for 6 months after the termination of the 6-month course (6-month-IFN-group). Sustained virological response (SVR) was defined as negative HCV-RNA at both 3 and 6 months after the completion of IFN therapy. Results: SVR was noted in 73.2% (30/41) of long-term-IFN-group and 18.2% (55/302) of 6-month-IFN-group. Multivariate analysis showed that long-term IFN therapy was the most significant contributor to SVR (p < 0.0001). Conclusion: Sustained negativity of HCV-RNA for 24 or more months by long-term IFN therapy correlated with SVR in patients with genotype 1b and high viral load.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus loadThe Esophagus, 2003
- Viral Dynamics and Pharmacokinetics in Combined Interferon Alfa-2b and Ribavirin Therapy for Patients Infected with Hepatitis C Virus of Genotype 1b and High Pretreatment Viral LoadIntervirology, 2002
- Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C: Results of a multicenter randomized trialJournal of Hepatology, 1997
- Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis c responding in a sustained fashion to interferon alfa-2b treatment*1Hepatology, 1995
- Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trialHepatology, 1995
- Classification of chronic hepatitis: Diagnosis, grading and stagingHepatology, 1994
- Factors predictive of response to interferon-α therapy in hepatitis C virus infectionHepatology, 1994
- High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeksHepatology, 1994
- Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and diseaseHepatology, 1994
- Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis CHepatology, 1991